Skip to main content
. 2023 Jun 8;12(12):1592. doi: 10.3390/cells12121592

Figure 2.

Figure 2

Generation of GPCs from iPSC lines: (A) ICC images of healthy control (HC) and Parkinson’s disease LRRK2-I1371V (PD) iPSCs for pluripotency markers Oct4, Tra-1-60, Nanog, and SSEA4. (B) ICC images of neural progenitor cells (NPs) from the healthy control and the LRRK2-I1371V iPSC line staining positive for NP cell markers nestin, musashi12, A2B5, and S100β; magnification 40×. (C) Flow cytometry histogram of NPs differentiated from the HC and PD iPSC lines immunolabeled with nestin, A2B5, musashi12, and S100β. (D) ICC images of glial progenitor cells (GPCs) from HC and PD iPSCs staining positive for GPC markers vimentin and nuclear factor 1A (NF1A). (E,F) qPCR analysis of GPC markers CD44 (E) and NF1A (F) of GPCs derived from HC and PD iPSCs. (G) Flow cytometry histogram of GPCs immunolabeled with vimentin and NF1A. The nuclei in the ICC images were counterstained with DAPi. n = 5; mean ± SD; w.r.t, with respect to.